HARP - Dosing underway in Harpoon Therapeutics' HPN328 study in small cell lung cancer

Harpoon Therapeutics (HARP) has dosed the first patient with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer ((SCLC)) and other tumors associated with DLL3 expression.The trial plans to enroll patients with SCLC that have relapsed following at least one line of platinum-based chemotherapy. The primary outcome measure will be to assess safety and tolerability, and to determine a dose for Phase 2. Following dose escalation, Harpoon may further evaluate the safety and efficacy of HPN328 in additional parallel cohorts.

For further details see:

Dosing underway in Harpoon Therapeutics' HPN328 study in small cell lung cancer